Haloperidol cardiovascular

The cardiovascular response to dopamine in humans depends on the concentration infused. Low rates of dopamine infusion can produce vasodilation in the renal, mesenteric, coronary, and intercerebral vascular beds with little effect on other blood vessels or on the heart. The vasodilation produced by dopamine is not antagonized by the p-adrenoceptor blocking agent propranolol but is antagonized by haloperidol and other dopamine receptor-blocking agents. 

D2-receptor activation gives Gai-mediated inhibition of adenylate cyclase (decreasing cAMP) and these receptors are involved in schizophrenia and Parkinson s disease and in control of motor function, cardiovascular function and behaviour by the CNS. The well-known antipsychotics chlorpromazine and haloperidol are D2-R antagonists. A number of hallucinogenic indole alkaloids from ergot-infected grasses and cereals are D2-R agonists (Table 5.4). 

In another trial olanzapine 2.5-7.5 mg/day was not associated with a higher risk of adverse cardiovascular events compared to typical neuroleptic drugs (haloperidol or promazine chlorhydrate) in 346 patients aged 71-92 years with vascular dementia and behavioral problems (603). 

Several cases of torsade de pointes have been reported with intravenous haloperidol used with lorazepam to treat delirium (SEDA-18, 30) (SEDA-18, 47). Acid mucopolysaccharide deposition may be associated with neuroleptic drug treatment as a possible mechanism contributing to rare cardiovascular adverse events (57). 

Angrist B, Sanfilipo M, Wolkin A. Cardiovascular effects of 0.5 milligrams per kilogram oral d-amphetamine and possible attenuation by haloperidol Clin Neuropharmacol 2001 24(3) 139-44. 

D6 Many cardiovascular and CNS drugs None known Haloperidol Quinidine Yes... 

Cardiovascular (CV) Sudden CV collapse/death Caution with antipsychotics, especially haloperidol... 

Butyrophenones, Phenylplperazines, and Related Compounds - Bromoperidol (6a) is essentially equal to haloperidol in potency and duration of action.18 The trans-4-aryl-4-methoxycyclohexylaminobutyrophenone 6b exceeded haloperidol on several behavioral endpoints and exhibited highly selective (vs. 5-HT) NE uptake blockade.1 Compound 6c, the most potent (15X CPZ in conditioned avoidance response [CAR]) in a series of substituted pyrazlno[2 ,1 6,l]pyrldo[3,4-b]lndoles, was reported to have a prolonged duration of action and few cardiovascular... 

---